What Are We Missing Daraxonrasib: A New Hope for Pancreatic Cancer
The US FDA approved the drug in August 2026. For Indian patients, however, the significance goes beyond the headline numbers.
A new drug is raising hopes in the treatment of advanced pancreatic cancer. Daraxonrasib, an oral RAS inhibitor, produced a striking survival benefit in the phase 3 RASolute 302 trial, with median overall survival of 13.2 months versus 6.7 months with chemotherapy in previously treated metastatic pancreatic cancer.
The US FDA approved the drug in August 2026. For Indian patients, however, the significance goes beyond the headline numbers.
Dr M. V. T. Krishna Mohan, Consultant Medical Oncologist, Basavatarakam Indo-American Cancer Hospital & Research Institute, says the results are genuinely exciting. “Pancreatic cancer remains one of the most difficult cancers to treat, particularly after first-line therapy has failed. In such patients, doubling median overall survival is a significant development. It potentially changes what we can offer in the second-line setting.”
CAN IT CHANGE PANCREATIC-CANCER TREATMENT?
RAS is a major driver of pancreatic cancer and has long been difficult to target. Daraxonrasib marks an important step towards directly targeting this pathway. But Dr Mohan urges caution. “We still do not know whether the trial results will translate into clinical practice in India. Indian patients with similar mutations may respond similarly, but this needs to be demonstrated in real-world practice.”
The trial results are encouraging, but Indian oncologists will need real-world experience to assess tolerability, treatment continuity and longer-term response.
TEST BEFORE YOU TREAT
For Indian patients, early molecular testing could become increasingly important, says Dr Mohan. Rather than waiting until treatment options are exhausted, he recommends testing at diagnosis to help plan treatment. “It is good to advise molecular testing at the time of initial diagnosis so that we can have a treatment plan in place. Test before you treat.”
THE QUESTIONS THAT REMAIN
The excitement comes with important caveats. “We still need answers about long-term survival, treatment after multiple lines of therapy and what happens when patients cannot tolerate the trial dose or duration,” says Dr Mohan. “For India, there are also practical questions around availability, affordability and access. US FDA approval does not automatically mean the drug is approved or commercially available here.”
WHAT IT MEANS FOR PATIENTS
Dr Deleep Kumar Gudipudi, Consultant Radiation Oncologist, Basavatarakam Indo-American Cancer Hospital
· Daraxonrasib is a new oral RAS-targeted treatment for metastatic pancreatic cancer after prior therapy.
· In a phase 3 trial, median overall survival was 13.2 months versus 6.7 months with standard chemotherapy.
· RAS mutations occur in more than 90% of pancreatic cancers, making this a significant development in targeting a long-elusive pathway.
· It is not a cure, and longer follow-up is needed to understand the durability of benefit.
· Molecular testing remains important to identify other actionable alterations and guide treatment.
· First-line studies are now exploring whether targeting RAS earlier can deliver greater benefit.
